Additionally, the detection of a TFG::ROS1 fusion in an ALK-negative inflammatory myofibroblastic tumor and the neoadjuvant use of crizotinib in that patient demonstrate the expanding relevance of targeted therapies in pediatric pulmonary malignancies. Here, ROS1 is linked to inflammatory myofibroblastic tumor.